[
  {
    "ts": null,
    "headline": "FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc. (NYSE:MRK) drugs with multibillion-dollar potential, according to internal documents seen by Reuters. Merck’s cholesterol pill enlicitide decanoate […]",
    "url": "https://finnhub.io/api/news?id=a08b5dcd8f74fc1b116cab6db1d48057b19d10fd09bbea58ad934ad2c98ae45f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767135944,
      "headline": "FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential",
      "id": 137950300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc. (NYSE:MRK) drugs with multibillion-dollar potential, according to internal documents seen by Reuters. Merck’s cholesterol pill enlicitide decanoate […]",
      "url": "https://finnhub.io/api/news?id=a08b5dcd8f74fc1b116cab6db1d48057b19d10fd09bbea58ad934ad2c98ae45f"
    }
  },
  {
    "ts": null,
    "headline": "BMY vs AMGN: Which Biotech Stock Is More Resilient Now?",
    "summary": "AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.",
    "url": "https://finnhub.io/api/news?id=fb26d8e8074750d7c719c4a173a8088ffa55da5a5f4fd470ed52b49edf6cbe52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767118920,
      "headline": "BMY vs AMGN: Which Biotech Stock Is More Resilient Now?",
      "id": 137943948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.",
      "url": "https://finnhub.io/api/news?id=fb26d8e8074750d7c719c4a173a8088ffa55da5a5f4fd470ed52b49edf6cbe52"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck (MRK) is a Top Value Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=8b48d30d95a08160fc82a16b3e0bd05951a8e0a5cb6146606270598e056e244b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767105603,
      "headline": "Why Merck (MRK) is a Top Value Stock for the Long-Term",
      "id": 137941951,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=8b48d30d95a08160fc82a16b3e0bd05951a8e0a5cb6146606270598e056e244b"
    }
  },
  {
    "ts": null,
    "headline": "3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains",
    "summary": "Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.",
    "url": "https://finnhub.io/api/news?id=52fbed3b5a0e5ecc7e3763f336b68aeb43f346ee25b9db555a7d359898e73d26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767099540,
      "headline": "3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains",
      "id": 137940276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.",
      "url": "https://finnhub.io/api/news?id=52fbed3b5a0e5ecc7e3763f336b68aeb43f346ee25b9db555a7d359898e73d26"
    }
  },
  {
    "ts": null,
    "headline": "Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis",
    "summary": "Merck stock earns a cautious \"Buy.\" Learn more about its valuation, Keytruda risks, pipeline potential, and long-term growth.",
    "url": "https://finnhub.io/api/news?id=63d132e6f96f129d0cde4e134bf10b95738e4cfb82b7aad57a5f14703d62c4d4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767096229,
      "headline": "Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis",
      "id": 137941359,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2161348087/image_2161348087.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck stock earns a cautious \"Buy.\" Learn more about its valuation, Keytruda risks, pipeline potential, and long-term growth.",
      "url": "https://finnhub.io/api/news?id=63d132e6f96f129d0cde4e134bf10b95738e4cfb82b7aad57a5f14703d62c4d4"
    }
  },
  {
    "ts": null,
    "headline": "Where is Merck & Co. (MRK) Headed According to Wall Street?",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best affordable healthcare stocks to buy now. Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Merck & Co., Inc. (NYSE:MRK) on December 19 and set a $139.00 price target. The same day, Merck & Co., Inc. (NYSE:MRK) announced a historic agreement with the Trump administration to […]",
    "url": "https://finnhub.io/api/news?id=f4c5a3792a78e26e83cf41bfcb76644e263a2097c0a6c2ad4f1131a9a43b96e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767070782,
      "headline": "Where is Merck & Co. (MRK) Headed According to Wall Street?",
      "id": 137940359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best affordable healthcare stocks to buy now. Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Merck & Co., Inc. (NYSE:MRK) on December 19 and set a $139.00 price target. The same day, Merck & Co., Inc. (NYSE:MRK) announced a historic agreement with the Trump administration to […]",
      "url": "https://finnhub.io/api/news?id=f4c5a3792a78e26e83cf41bfcb76644e263a2097c0a6c2ad4f1131a9a43b96e0"
    }
  }
]